Abivax SA (ABVX) UC Opportunity: Oral Therapy Catalyst
Analyst Consensus Report

1. Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Disclosures for Laidlaw & Co., Abivax, June, 29, 2026:

ANALYST CERTIFICATION The analyst responsible for the content of this report hereby certifies that the views expressed regarding the company or companies and their securities accurately represent his/her personal views and that no direct or indirect compensation is to be received by the analyst for any specific recommendation or views contained in this report. Neither the author of this report nor any member of his immediate family or household maintains a position in the securities mentioned in this report. EQUITY DISCLOSURES For the purpose of ratings distributions, regulatory rules require the firm to assign ratings to one of three rating categories (i.e., Strong Buy/Buy-Overweight, Hold, or Underweight/Sell) regardless of a firm's own rating categories. Although the firm’s ratings of Buy/Overweight, Hold, or Underweight/Sell most closely correspond to Buy, Hold and Sell, respectively, the meanings are not the same because our ratings are determined on a relative basis against the analyst sector universe of stocks. An analyst's coverage sector is comprised of companies that are engaged in similar business or share similar operating characteristics as the subject company. The analysis sector universe is a sub-sector to the analyst's coverage sector, and is compiled to assist the analyst in determining relative valuations of subject companies. The composition of an analyst's sector universe is subject to change over time as various factors, including changing market conditions occur. Accordingly, the rating assigned to a particular stock represents solely the analyst's view of how that stock will perform over the next 12-months relative to the analyst's sector universe. Additional information available upon request.

ADDITIONAL DISCLOSURES As of the date of this report, neither the author of this report nor any member of his immediate family or household maintains an ownership position in the securities of the company (ies) mentioned in this report. This report does not provide individually tailored investment advice and has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. Laidlaw & Co (UK), Ltd. recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. The securities, instruments, or strategies discussed in this report may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. This report is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. Associated persons of Laidlaw & Co (UK), Ltd not involved in the preparation of this report may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned herein and may trade them in ways different from those discussed in this report. While Laidlaw & Co (UK), Ltd., prohibits analysts from receiving any compensation. Bonus or incentive based on specific recommendations for, or view of, a particular company, investors should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. With the exception of information regarding Laidlaw & Co (UK), Ltd. this report is based on public information. Laidlaw & Co (UK), Ltd makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete and it should not be relied upon as such. Any opinions expressed are subject to change and Laidlaw & Co (UK), Ltd disclaims any obligation to advise you of changes in opinions or information or any discontinuation of coverage of a subject company. Facts and views presented in this report have not been reviewed by, and may not reflect information known to, professionals in other Laidlaw & Co (UK), Ltd business areas. Laidlaw & Co (UK), Ltd associated persons conduct site visits from time to time but are prohibited from accepting payment or reimbursement by the company of travel expenses for such visits. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices. market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments. Any trademarks and service marks contained in this report are the property of their respective owners. Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data. This report or any portion thereof may not be reprinted, sold or redistributed without the written consent of Laidlaw & Co (UK), Ltd. This report is disseminated and available primarily electronically, and, in some cases, in printed form. The information and opinions in this report were prepared by Laidlaw & Co (UK), Ltd. For important disclosures, please see Laidlaw & Co (UK), Ltd.’s disclosure website at www.Laidlawltd.com, or contact your investment representative or Laidlaw & Co (UK), Ltd at 521 Fifth Ave, 12th Floor, New York, NY 10175 USA.

Disclosures for LifeSci Capital, Abivax, June 30, 2026:

Analyst Certification I, Sam Slutsky, certify that: (1) all of the views expressed in this report accurately reflect my personal views about any and all of the subject securities or subject companies, and (2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this report. I, Kate Dellorusso, certify that: (1) all of the views expressed in this report accurately reflect my personal views about any and all of the subject securities or subject companies, and (2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this report. DISCLOSURES An affiliate of LifeSci Capital LLC has provided non-investment banking securities-related services, non-securities services, and other products or services other than investment banking services to Abivax S.A. and received compensation for such services within the past 12 months. LifeSci Capital LLC or affiliates has managed or co-managed a public offering of securities for ABVX in the past 12 months. LifeSci Capital LLC or affiliates has received compensation for investment banking services from ABVX in the past 12 months. ABVX has been an investment banking client of LifeSci Capital LLC within the past 12 months.

This report has been prepared by LifeSci Capital LLC (“LSC”), solely for the purpose of supplying information to the clients of LSC and/or its affiliates to whom it is distributed. This report is not, and should not be construed as, a solicitation or offer to buy or sell any securities or related financial products. This report has been prepared by LSC solely from publicly available information. The information contained herein is believed to be reliable but has not been independently verified. LSC makes no guarantee, representation or warranty, and LSC and affiliates, directors, employees or agents accept no responsibility or liability whatsoever as to the accuracy, completeness or appropriateness of such information or for any loss or damage arising from the use or further communication of this report or any part of it. Information contained herein may not be current due to, among other things, changes in the financial markets or economic environment. Opinions reflected in this report are subject to change without notice. This report does not constitute and should not be used as a substitute for tax, legal or investment advice. The report has been prepared without regard to the individual financial circumstances, needs or objectives of persons who receive it. The securities and investments related to the securities discussed in this report may not be suitable for all investors and is intended for institutional investor use only. Readers should independently evaluate particular investments and strategies and seek the advice of a financial adviser before making any investment or entering into any transaction in relation to the securities mentioned in this report. An internal generative artificial intelligence (“AI”) tool may have been used in the preparation of this material, including assisting in fact-finding, data gathering and analysis, pattern recognition, and content drafting. Notwithstanding any such use of AI tools, this document has undergone human review prior to publishing. LSC has no legal responsibility to any investor who directly or indirectly receives this material. Investment decisions are to be made by and remain as the sole responsibility of the investor. Investment involves risks. The price of securities may go down as well as up, and under certain circumstances investors may sustain total loss of investment. Past performance should not be taken as an indication or guarantee of future performance. Unless otherwise attributed, forecasts of future performance represent analysts’ estimates based on factors they consider relevant. Actual performance may vary. Consequently, no express or implied warranty can be made regarding future performance. The authors of this report are prohibited from using any material, non-public or insider information.

LSC has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which LSC relies, to manage potential conflicts of interest and control the flow of information within departments of LSC and among its affiliates. LSC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. LSC or other companies affiliated with LSC, together with their respective directors and officers, may have or take positions in the securities mentioned in this report, or derivatives of such securities or other securities issued by companies mentioned in this report, for their own account or the accounts of others, or enter into transactions contrary to any recommendations contained herein, and also may perform or seek to perform broking and other investment or securities related services for the companies mentioned in this report as well as other parties generally. Please visit https://lifesci.bluematrix.com/sellside/Disclosures.action for disclosures related to each company that is a subject of this report. Alternatively, please contact us by telephone at (646) 876-5059 or by mail at LifeSci Capital LLC, Attn: Compliance, 1700 Broadway, 40th Floor, New York, NY 10019 to obtain disclosures relating to any of the companies that are the subject of this report. Restrictions on Distribution This report is not directed to, or intended for distribution to or use by, any person who is a citizen or resident of, or entity located in, any locality, territory, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to or restricted by law or regulation. Persons or entities into whose possession this report comes should inform themselves about and observe such restrictions. United States: LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, USA, contact number +1-646-847-1400, distributes or approves the distribution of this report in the United States and takes responsibility for it. Any transaction by a US investor resulting from the information contained in this report may be affected only through LSC. Interested US investors should contact their LSC sales representative. © LifeSci Capital LLC. All Rights Reserved 2026. This document may not be altered, reproduced (including for purposes of training artificial intelligence models or tools), redistributed, passed on to any other party or used to create derivative works, in whole or in part, without the prior written consent of LifeSci Capital, LLC.

Disclosures for Webush, Abivax, June 30, 2026:

Analyst Certification: We, David Nierengarten, Martin Fan and Dennis Pak, certify that the views expressed in this report accurately reflect our personal opinions and that we have not and will not, directly or indirectly, receive compensation or other payments in connection with our specific recommendations or views contained in this report.

The Distribution of Ratings is required by FINRA rules; however, WS' stock ratings of Outperform, Neutral, and Underperform most closely conform to Buy, Hold, and Sell, respectively. Please note, however, the definitions are not the same as WS' stock ratings are on a relative basis. The analysts responsible for preparing research reports do not receive compensation based on specific investment banking activity. The analysts receive compensation that is based upon various factors including WS' total revenues, a portion of which are generated by WS' investment banking activities. Company Specific Disclosures This information is subject to change at any time. This research is provided for educational and informational purposes only and is not intended to be relied upon as a forecast, research, or investment advice, and is not a recommendation, offer, or solicitation to buy or sell any securities or to adopt any investment strategy. Investing involves risk, including the risk of loss of principal. Your investments may decline in value due to both real and perceived general market, economic, and industry conditions. Diversification does not ensure profits or protect against loss. This research was prepared without regard to specific investment objectives, strategies, tax status, investment horizon, financial situation or needs of any investor. Wedbush Securities, Inc. (“WSI”) encourages recipients of this report to read all relevant offering documents (e.g., prospectus) pertaining to any investment concerned, including without limitation, information relevant to its investment objectives, risks, and costs before making an investment decision and when deemed necessary, to seek the advice of a legal, tax, and/or accounting professional. Past performance is no guarantee of future results. Reliance upon information in this research is at the sole discretion of the reader. All information in this research is believed to be reliable as of the date on which this research was issued and has been obtained from public sources believed to be reliable. No representation or warranty, either express or implied, is provided in relation to the accuracy or completeness of the information contained herein. The opinions expressed are as of the date written and are subject to change without notice. In addition, this research may contain certain statements deemed to be “forward-looking” statements. All statements, other than historical facts, contained within this document that address activities, events or developments that this research report expects, believes, or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions and analyses made by WSI in light of its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. Such statements are subject to assumptions, risks, uncertainties, many of which are beyond WSI’s control. Please note that any such statements are not guarantees of any future performance and that actual results or developments may differ materially from those projected in the forward-looking statements. Prepared by Wedbush Securities, Inc., a member of FINRA and SIPC. 1. WS makes a market in the securities of Abivax S.A.

Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available on request. Disclosure information regarding historical ratings and price targets is available: Research Disclosures Applicable disclosure information is also available upon request by contacting the Research Department at (212) 833-1375, by email to [email protected]. You may also submit a written request to the following: Wedbush Securities, Attn: Research Department, 142 W 57th Street, New York, NY 10019. OTHER DISCLOSURES The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis: neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The herein mentioned securities may be sold to or bought from customers on a principal basis by this firm. Additional information with respect to the information contained herein may be obtained upon request. Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Retail Investors The information provided is for general informational purposes only and should not be considered an individual recommendation or personalized investment advice. The companies/investments mentioned may not be suitable for everyone. Each investor needs to review their own respective situation(s) before making any investment decisions. All expressions of opinion are subject to change without notice due to shifting market(s), economic or political conditions. Investment involves risks including the risk of principal. Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.

The market for treatments targeting chronic inflammatory conditions such as ulcerative colitis continues to expand as patients seek effective oral options that avoid injections or infusions. Abivax SA (ABVX:NASDAQ) is positioned to capture attention with its lead candidate that modulates the body's own regulatory pathways rather than broadly suppressing immunity.

Retail investors evaluating biotechnology names often look first at late-stage clinical progress and upcoming regulatory milestones. Abivax meets those criteria through positive data from its completed ABTECT program in ulcerative colitis, setting the stage for a potential New Drug Application filing.

Market Opportunity in Inflammatory Bowel Disease

Ulcerative colitis and Crohn's disease together represent a large and growing segment within immunology.

Patients with moderate to severe disease frequently cycle through multiple therapies, creating demand for new mechanisms that deliver durable responses with convenient dosing. An oral once-daily small molecule like obefazimod could address gaps left by existing injectable or infused treatments.

Why Abivax Stands Out

Founded in 2013 by immunologist Philippe Pouletty, the Paris-headquartered company maintains R&D operations in France and a U.S. office in Waltham, Massachusetts. Its sole clinical-stage asset, obefazimod (formerly ABX464), is the first molecule designed to increase expression of microRNA-124, a natural regulator that helps control inflammatory signaling. This differentiated approach may offer advantages in both efficacy and long-term safety compared with broader immunosuppressants.

Key Assets and Development Programs

Obefazimod has advanced furthest in ulcerative colitis. The pivotal Phase 3 ABTECT induction trials (ABTECT-1 and ABTECT-2) produced positive eight-week topline results in mid-2025. The 44-week maintenance portion delivered positive topline data on June 1, 2026, with both the 25-milligram and 50-milligram doses meeting the primary endpoint while maintaining a favorable safety profile.

A separate Phase 2b ENHANCE-CD trial in Crohn's disease began enrollment in the third quarter of 2024, with 12-week induction results expected in mid-2027. The company is also exploring additional candidates from its proprietary library of miR-124 enhancers.

Upcoming Catalysts and Regulatory Timeline

The most immediate value driver is the planned New Drug Application submission to the U.S. Food and Drug Administration for obefazimod in ulcerative colitis, targeted for late fourth quarter 2026 after a scheduled pre-NDA meeting. Additional milestones include topline Crohn's disease data in 2027 and potential selection of a combination therapy candidate by the end of 2026.

Key Investor Takeaways

• Obefazimod's novel enhancement of microRNA-124 provides a differentiated mechanism in a competitive ulcerative colitis landscape.
• Positive Phase 3 induction and maintenance data support an NDA filing targeted for late 2026, creating a clear regulatory catalyst.
• Analyst price targets range from US$110 to CA$170, reflecting varied views on safety interpretation and commercial potential.
• Institutional ownership near 50 percent signals professional investor interest, while retail investors still hold a meaningful portion of shares.
• Expansion into Crohn's disease and follow-on miR-124 candidates offers longer-term pipeline optionality beyond the initial ulcerative colitis indication.

Analyst Perspectives and Valuation Views

Recent research notes highlight both enthusiasm and caution around the safety dataset. Laidlaw & Co. analyst Yale Jen reiterated a Buy rating and CA$160 12-month target, citing the innovative mechanism and de-risked induction results while viewing the stock as undervalued and a potential acquisition candidate. LifeSci Capital analyst Sam Slutsky maintained an Outperform rating and CA$170 target based on a DCF model projecting risk-adjusted peak sales of US$3.8 billion in ulcerative colitis and US$2.7 billion in Crohn's disease. Wedbush analyst David Nierengarten kept a Neutral rating but raised the target to US$110, noting ongoing questions about malignancy signals and the possibility of a boxed warning.

Other firms have adjusted targets in recent weeks. BTIG reiterated Buy and lifted its target to US$175, while Jefferies upgraded back to Buy with a US$158 target. Citizens and Truist Securities also reaffirmed positive ratings with targets between US$155 and US$187. These shifts illustrate how fresh maintenance data can influence sentiment even as some firms remain cautious on regulatory perception.

Share Structure and Ownership Profile

Abivax SA carries a market capitalization of US$11.6 billion with 79.29 million shares outstanding. The 52-week trading range spans US$6.20 to US$132.

¹Institutions hold 49.56 percent of shares, strategic investors own 5.3 percent, and the remainder is held by retail investors.

Common Questions from Investors

Q: What is the primary endpoint met in the ABTECT maintenance trial? A: Both the 25-milligram and 50-milligram doses achieved the primary endpoint with a favorable safety profile at 44 weeks.

Q: When could obefazimod reach the U.S. market? A: The company targets an NDA submission in late 2026, which could lead to potential approval and launch in 2027 if the review proceeds smoothly.

Q: How does the company address malignancy concerns? A: Additional safety analyses using exposure-adjusted incidence rates showed no clear malignancy signal in part two of the maintenance study.

Q: What is the peak sales potential modeled by analysts? A: Models assume risk-adjusted global peak sales of approximately US$3.8 billion in ulcerative colitis and US$2.7 billion in Crohn's disease.

Q: Does Abivax have other assets beyond obefazimod? A: The company continues to research follow-on candidates from its proprietary library of miR-124 enhancers.

Abivax SA offers retail investors exposure to a late-stage oral therapy with a novel mechanism in a sizable inflammatory disease market. The upcoming NDA submission and additional clinical readouts provide defined milestones against which progress can be measured.